New combo aims to stop nausea in breast cancer patients

NCT ID NCT07254416

Not yet recruiting Symptom relief Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of two anti-nausea drugs (NEPA plus megestrol acetate) works better than the standard regimen (NEPA plus dexamethasone) for preventing nausea and vomiting in breast cancer patients receiving T-DXd therapy. 120 participants will be randomly assigned to one of the two groups. The goal is to improve quality of life and help patients stay on their cancer treatment without dose reductions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NEPA (netupitant/palonosetron), megestrol acetate, dexamethasone
What this could lead to: If successful, this could offer a better way to prevent nausea and vomiting in breast cancer patients on T-DXd, improving quality of life and reducing treatment interruptions.
What could go wrong: This is a small, early-stage trial (Phase 4) with only 120 participants. The new combination may not be more effective than the standard regimen, and side effects from the drugs themselves are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER PATIENTS TREATED WITH T-DXD

More trials for these conditions

Other studies related to the condition(s) this trial covers.